Clinical Trial Update: Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial using a lentiviral vector gene therapy to treat X-linked chronic granulomatous disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Granulomatous Disease

Drugs mentioned

• Lentiviral vector gene therapy for X-linked chronic granulomatous disease

Snippet

Sponsor: University of California, Los Angeles | Conditions: Granulomatous Disease, Chronic, X-linked | Phase 1, Phase 2 | Status: COMPLETED